[go: up one dir, main page]

MX2021000375A - Degradadores selectivos del receptor de estrogeno. - Google Patents

Degradadores selectivos del receptor de estrogeno.

Info

Publication number
MX2021000375A
MX2021000375A MX2021000375A MX2021000375A MX2021000375A MX 2021000375 A MX2021000375 A MX 2021000375A MX 2021000375 A MX2021000375 A MX 2021000375A MX 2021000375 A MX2021000375 A MX 2021000375A MX 2021000375 A MX2021000375 A MX 2021000375A
Authority
MX
Mexico
Prior art keywords
estrogen receptor
selective estrogen
sup
sub
receptor degraders
Prior art date
Application number
MX2021000375A
Other languages
English (en)
Inventor
Almudena Rubio
Jolie Anne Bastian
Jeffrey Daniel Cohen
Daniel Jon Sall
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67470734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021000375(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2021000375A publication Critical patent/MX2021000375A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Finger-Pressure Massage (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

Se proporcionan novedosos degradadores selectivos del receptor de estrógeno (SERD) de acuerdo con la fórmula: (ver fórmula) sales aceptables desde el punto de vista farmacéutico de estos y composiciones farmacéuticas de estos, en donde ya sea R1 o R2 se selecciona independientemente de Cl, F, -CF3, o -CH3, y el otro es hidrógeno, y métodos para su uso.
MX2021000375A 2018-07-12 2019-07-11 Degradadores selectivos del receptor de estrogeno. MX2021000375A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862697100P 2018-07-12 2018-07-12
PCT/US2019/041334 WO2020014435A1 (en) 2018-07-12 2019-07-11 Selective estrogen receptor degraders

Publications (1)

Publication Number Publication Date
MX2021000375A true MX2021000375A (es) 2021-05-27

Family

ID=67470734

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021000375A MX2021000375A (es) 2018-07-12 2019-07-11 Degradadores selectivos del receptor de estrogeno.
MX2023006047A MX2023006047A (es) 2018-07-12 2021-01-11 Degradadores selectivos del receptor de estrogeno.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023006047A MX2023006047A (es) 2018-07-12 2021-01-11 Degradadores selectivos del receptor de estrogeno.

Country Status (37)

Country Link
US (4) US10654866B2 (es)
EP (2) EP4155310A1 (es)
JP (6) JP6995241B2 (es)
KR (3) KR102783756B1 (es)
CN (2) CN112638916B (es)
AR (2) AR115694A1 (es)
AU (2) AU2019299947B2 (es)
BR (1) BR122023025061A2 (es)
CA (1) CA3105501C (es)
CL (1) CL2021000045A1 (es)
CO (1) CO2021000043A2 (es)
CR (1) CR20210007A (es)
DK (1) DK3820873T3 (es)
EA (1) EA202092975A1 (es)
EC (1) ECSP21001770A (es)
ES (1) ES2933980T3 (es)
FI (1) FI3820873T3 (es)
HR (1) HRP20230009T1 (es)
HU (1) HUE060963T2 (es)
IL (3) IL289871B2 (es)
JO (1) JOP20210005A1 (es)
LT (1) LT3820873T (es)
MA (2) MA53124B1 (es)
MD (1) MD3820873T2 (es)
MX (2) MX2021000375A (es)
MY (1) MY198962A (es)
PE (1) PE20210400A1 (es)
PH (1) PH12021550049A1 (es)
PL (1) PL3820873T3 (es)
PT (1) PT3820873T (es)
RS (1) RS63809B1 (es)
SA (1) SA521421008B1 (es)
SG (1) SG11202100148TA (es)
SI (1) SI3820873T1 (es)
TW (1) TWI702219B (es)
UA (1) UA127507C2 (es)
WO (1) WO2020014435A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA122346C2 (uk) 2015-10-01 2020-10-26 Олема Фармасьютикалз, Інк. ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ
WO2020014440A1 (en) * 2018-07-12 2020-01-16 Eli Lilly And Company Selective estrogen receptor degraders
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
JP7616794B2 (ja) 2019-07-07 2025-01-17 オレマ ファーマシューティカルズ インク． エストロゲン受容体アンタゴニストのレジメン
IL293252A (en) 2019-12-09 2022-07-01 Sanofi Sa Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
IL303041A (en) * 2020-11-23 2023-07-01 Sanofi Sa Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
AU2022222660A1 (en) * 2021-02-16 2023-07-27 Genentech, Inc. Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib
CN114957114A (zh) * 2021-02-26 2022-08-30 冷志 一种4-溴-3-氯-7-甲氧基喹啉的合成方法
CN117042771A (zh) * 2021-03-09 2023-11-10 伊莱利利公司 使用serd给药方案的组合治疗癌症的方法
TWI837605B (zh) * 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
TWI894443B (zh) * 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
AU2023216654B2 (en) * 2022-02-01 2025-09-25 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders
TW202430176A (zh) 2022-10-17 2024-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
CN120456897A (zh) 2022-11-02 2025-08-08 佩特拉制药公司 用于治疗疾病的磷酸肌醇3-激酶(pi3k)变构色原酮抑制剂
CN120187416A (zh) 2022-11-11 2025-06-20 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
US20240180893A1 (en) 2022-11-17 2024-06-06 Astrazeneca Ab Methods of treatment of breast cancer
AU2024268541A1 (en) 2023-05-05 2025-11-20 Eli Lilly And Company Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer
AU2024268579A1 (en) 2023-05-11 2026-01-15 Astrazeneca Ab Combination of a parp1 inhibitor and a selective estrogen degrader for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395563B1 (en) * 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US7329654B2 (en) * 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
MXPA04010433A (es) * 2002-04-19 2005-08-19 Signal Pharm Inc Compuestos benzopiranona, composiciones de estos y los metodos para el tratamiento con estos.
US20090023917A1 (en) * 2004-01-22 2009-01-22 Eli Lilly And Company Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms
US20080221163A1 (en) * 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
EP3233828B1 (en) * 2014-12-18 2020-03-04 F. Hoffmann-La Roche AG Estrogen receptor modulators and uses thereof
IL301960B2 (en) * 2014-12-18 2024-08-01 Hoffmann La Roche Tetrahydro-pyrido[3, 4-b]indole estrogen receptor modulators and their uses
WO2018108954A1 (en) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
WO2020014440A1 (en) * 2018-07-12 2020-01-16 Eli Lilly And Company Selective estrogen receptor degraders
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
FI3820873T3 (fi) 2023-03-02
IL280065B (en) 2022-04-01
MD3820873T2 (ro) 2023-05-31
JP2025186400A (ja) 2025-12-23
EP4155310A1 (en) 2023-03-29
UA127507C2 (uk) 2023-09-13
JP2021530484A (ja) 2021-11-11
JP2022050591A (ja) 2022-03-30
BR122023025061A2 (pt) 2024-02-20
CR20210007A (es) 2021-02-08
AU2022203969A1 (en) 2022-06-30
IL295598B1 (en) 2023-05-01
US10654866B2 (en) 2020-05-19
IL289871A (en) 2022-03-01
SG11202100148TA (en) 2021-02-25
JP2023081954A (ja) 2023-06-13
SA521421008B1 (ar) 2022-10-30
PT3820873T (pt) 2022-12-23
KR20210019065A (ko) 2021-02-19
CN112638916A (zh) 2021-04-09
ES2933980T3 (es) 2023-02-15
IL280065A (en) 2021-03-01
LT3820873T (lt) 2023-01-10
MA53126B1 (fr) 2023-02-28
MA53126A (fr) 2021-05-19
SI3820873T1 (sl) 2023-02-28
MA53124B1 (fr) 2023-02-28
RS63809B1 (sr) 2023-01-31
IL289871B2 (en) 2023-02-01
PL3820873T3 (pl) 2023-02-13
CN112638916B (zh) 2023-09-12
AU2022203969B2 (en) 2024-02-15
NZ771718A (en) 2024-05-31
US11634426B2 (en) 2023-04-25
TW202019935A (zh) 2020-06-01
IL289871B (en) 2022-10-01
JP2022037102A (ja) 2022-03-08
AU2019299947A1 (en) 2021-01-07
TWI702219B (zh) 2020-08-21
US20200347073A1 (en) 2020-11-05
JOP20210005A1 (ar) 2021-01-10
CN117379428A (zh) 2024-01-12
US20210403480A1 (en) 2021-12-30
JP2024169490A (ja) 2024-12-05
US11117902B2 (en) 2021-09-14
DK3820873T3 (da) 2022-12-12
KR20230005404A (ko) 2023-01-09
BR112020025654A2 (pt) 2021-04-06
JP7241211B2 (ja) 2023-03-16
MY198962A (en) 2023-10-05
AR134487A2 (es) 2026-01-21
MX2023006047A (es) 2023-06-02
US11993608B2 (en) 2024-05-28
JP7557564B2 (ja) 2024-09-27
KR102783756B1 (ko) 2025-03-21
PH12021550049A1 (en) 2021-09-20
WO2020014435A1 (en) 2020-01-16
MA53124A (fr) 2021-05-19
KR20230148386A (ko) 2023-10-24
HUE060963T2 (hu) 2023-04-28
PE20210400A1 (es) 2021-03-02
KR102550538B1 (ko) 2023-07-04
US20230234960A1 (en) 2023-07-27
EA202092975A1 (ru) 2021-04-14
HRP20230009T1 (hr) 2023-02-17
IL295598B2 (en) 2023-09-01
JP7009672B1 (ja) 2022-01-25
IL295598A (en) 2022-10-01
CA3105501C (en) 2023-10-31
JP7746496B2 (ja) 2025-09-30
ECSP21001770A (es) 2021-02-26
CL2021000045A1 (es) 2021-07-19
CO2021000043A2 (es) 2021-01-18
KR102589886B1 (ko) 2023-10-17
AU2019299947B2 (en) 2022-03-17
AR115694A1 (es) 2021-02-17
EP3820873A1 (en) 2021-05-19
JP6995241B2 (ja) 2022-01-14
US20200017516A1 (en) 2020-01-16
EP3820873B1 (en) 2022-11-23
CA3105501A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
MX2023006047A (es) Degradadores selectivos del receptor de estrogeno.
PH12021550048A1 (en) Selective estrogen receptor degraders.
CR20200532A (es) Compuestos de heteroarilo tetracíclicos
MX384752B (es) ANTAGONISTAS SOLUBLES DE RECEPTOR DE C5a (C5aR).
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
CR20220234A (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
MX418519B (es) Inhibidores selectivos de jak1
MY201700A (en) Methods of making incretin analogs
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
SA522431429B1 (ar) Sting مركبات كبيرة الحلقات كمساعِدات وطرق واستخداماتها
EP4609866A3 (en) Oxysterols and methods of use thereof
MX2021004940A (es) Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos.
MX2024014845A (es) Esteroides neuroactivos no saturados 9(11) y sus metodos de uso
PH12019501724A1 (en) Estrogen receptor modulators
NZ786543A (en) Compounds active towards nuclear receptors
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
CR20210173A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2023010823A (es) Degradadores selectivos del receptor de estrogeno.
IL188927A0 (en) Aryloxy quinolines and uses thereof as 5-ht6 modulators
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
PH12022550860A1 (en) 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists
TN2018000175A1 (en) Indane derivatives as mglur7 modulators